hDHODH-IN-11 

hDHODH-IN-11 is a potent human dihydroorotate dehydrogenase (hDHODH) inhibitor with an IC₅₀ value of 7.2 nM. hDHODH-IN-11 has low cytotoxicity. hDHODH-IN-11 can be used in research of acute myeloid leukemia (AML)^[1].

IC50: 7.2 nM (hDHODH)^[1]

hDHODH-IN-11 (0.1 and 1 μM; 72 h; THP1 and U937 cells) has low cytotoxicity, pro-apoptotic and pro-differentiating abilities^[1].
hDHODH-IN-11 (0.1 μM; 72 h; THP1 and MV4-11 cells) with Dipyridamole (HY-B0312) results in synergistic effect and demonstrates a good pro-apoptotic activity^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

hDHODH-IN-11 (20 mg/kg; i.p.; daily, for 13 d; Balb/c mice with AML xenografts) reduces the leukemic burden and tumor weight^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

401.46

C₂₄H₂₃N₃O₃

2396653-34-0

O=C(C1=C2C=CC=CN2N=C1O)NC3=CC(C)=C(OC4=CC=CC=C4)C=C3C(C)C

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Sainas S, et, al. Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold: SAR of the Aryloxyaryl Moiety. J Med Chem. 2022 Oct 13;65(19):12701-12724.